Maritza Wilson
Family Medicine · Escondido, CANPI 1720465925
Payments from drug & device makers
Across 102 payments — averaging $46.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$3K
- Novo Nordisk$686
- Bayer$509
- Lilly USA, LLC$201
- Dexcom, Inc.$188
- Abbott$168
- plus $354 from 12 others
What the payments were for
- Travel & lodging$1,94141%
- Food & beverage$2,82859%
- Education$10%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 27 | $2,663 |
| Novo Nordisk | 29 | $686 |
| Bayer | 14 | $509 |
| Lilly USA, LLC | 8 | $201 |
| Dexcom, Inc. | 3 | $188 |
| Abbott | 2 | $168 |
| Organon | 4 | $67 |
| Insulet Corporation | 2 | $64 |
| Astellas Pharma US Inc | 2 | $47 |
| Cranial Technologies, Inc | 2 | $31 |
| Daiichi Sankyo Inc. | 2 | $31 |
| Phadia US Inc. | 1 | $28 |
| Corcept Therapeutics | 1 | $23 |
| Kowa Pharmaceuticals America, Inc. | 1 | $18 |
| Viiv Healthcare Company | 1 | $18 |
| Coopersurgical, Inc. | 1 | $14 |
| Sanofi Pasteur Inc. | 1 | $12 |
| Sumitomo Pharma America, Inc. | 1 | $1 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MINIMED 770G$1,773
- Kerendia$362
- Wegovy$236
- MitraClip$148
- DEXCOM G7 GSS (161)$140
- DEXCOM STELO GLUCOSE BIOSENSOR$140
- Minimed 670G System$111
How this compares
$4,769 in reported general payments places this provider in the 90th percentile of 10,533 family medicine providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 115 | $117,186 |
| TrulicityDulaglutide | 41 | $55,161 |
| JardianceEmpagliflozin | 35 | $53,016 |
| RybelsusSemaglutide | 28 | $31,667 |
| JanuviaSitagliptin Phosphate | 15 | $23,142 |
| TradjentaLinagliptin | 24 | $14,155 |
| EliquisApixaban | 11 | $12,447 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 19 | $11,075 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $3,726 |
| Lubiprostone | 19 | $3,228 |
| Atorvastatin Calcium | 172 | $1,935 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 49 | $1,538 |
| Rosuvastatin Calcium | 71 | $1,238 |
| Levothyroxine Sodium | 106 | $1,108 |
| VascepaIcosapent Ethyl | 13 | $1,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $686 | $148,853143 claims |
| Lilly USA, LLCTrulicity | $201 | $55,16141 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 10,533 family medicine providers in California.
Other family medicine in Escondido
- James SchultzEscondido$2.5M
- Amina HaggagNorthridge$112.8M
- Steven ReynoldsLong Beach$53M
- Rizwana MohseniLake Forest$26.7M
- Daniel JohnsonSan Diego$15.7M
- Stacey LayleSan Diego$14.8M
- Apinya VutikullirdCypress$14.3M
- Hanid AudishSpring Valley$13.6M
- Augusto FocilOxnard$12.6M
- Jack VuLong Beach$10.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.